| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Nurix Therapeutics, Inc. (NRIX) has 5 insiders with recent SEC Form 4 filings, including 0 buys and 10 sells. NRIX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 125.2K | $3.16M | -3,847 | |
| Other | 122.8K | $3.10M | -20,436 | |
| Dir | 50.0K | $1.26M | - | |
| CFO | 40.2K | $1.01M | -7,606 | |
| Dir | 10.8K | $271.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 31, 2023 | Hansen Gwenn72 | Chief Scientific Officer | Sale+OE | 1,633 | $5.20 | $8,487.35 | -4.6% | +49.7% | +330.6% | |
| Oct 31, 2023 | Van Houte Hans60 | Chief Financial Officer | Sale+OE | 1,080 | $5.20 | $5,613.19 | -1.2% | +49.7% | +330.6% | |
| Jul 31, 2023 | Van Houte Hans60 | Chief Financial Officer | Sale+OE | 1,245 | $9.65 | $12,020.10 | -1.5% | -45.8% | +113.9% | |
| Jul 31, 2023 | Ring Christine77 | General Counsel | Sale+OE | 1,420 | $9.65 | $13,709.67 | -10.2% | -45.8% | +113.9% | |
| Jul 31, 2023 | Hansen Gwenn72 | Chief Scientific Officer | Sale+OE | 1,884 | $9.65 | $18,189.45 | -5.9% | -45.8% | +113.9% | |
| May 1, 2023 | Wolff Stefani65 | EVP And COO | Sale+OE | 342 | $9.88 | $3,377.69 | -5.3% | -1.9% | +21.4% | |
| May 1, 2023 | Van Houte Hans60 | Chief Financial Officer | Sale+OE | 721 | $9.88 | $7,120.81 | -0.9% | -1.9% | +21.4% | |
| May 1, 2023 | Ring Christine77 | General Counsel | Sale+OE | 682 | $9.88 | $6,735.64 | -6.4% | -1.9% | +21.4% | |
| May 1, 2023 | Hansen Gwenn72 | Chief Scientific Officer | Sale+OE | 1,136 | $9.88 | $11,219.48 | -4.1% | -1.9% | +21.4% | |
| Jan 30, 2023 | Wolff Stefani65 | EVP And COO | Sale+OE | 424 | $11.78 | $4,994.55 | -9.7% | -16.6% | -32.7% |